CCO Treatment Updates
Managing Cardiovascular Risk in HIV-Infected Patients: The Role of Antiretroviral Selection
Latest Insights Into Cardiovascular Risk in HIV-Infected Patients |
Module 1 of 2 |
 
- Jens D. Lundgren, MD, DMSc
- Signe Westring Worm, MD
|
|
|
Jens D. Lundgren, MD, DMSc, and Signe Westring Worm, MD, review elements of cardiovascular risk including those unique to the HIV-infected population.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe how the epidemiology of cardiovascular risk is different in the HIV-infected population when compared with the general population
- Discuss the contribution of traditional risk factors to cardiovascular risk in HIV-infected patients
- Explain how untreated HIV contributes to cardiovascular risk in HIV-infected patients
- Relate how antiretroviral therapy contributes to cardiovascular risk in HIV-infected patients
- List several actions physicians may take to monitor and to mitigate cardiovascular risk in HIV-infected patients
|
Antiretroviral Strategies for Minimizing Cardiovascular Risk |
Module 2 of 2 |
|
|
|
Sally Hodder, MD, discusses antiretroviral strategies that may be used to manage cardiovascular risk in HIV-infected individuals.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the guidelines on cardiovascular risk management in HIV settings
- Explain the benefits and limitations of lipid-lowering therapy in HIV-infected patients
- Discuss data concerning the selection of antiretrovirals to minimize cardiovascular risk
- Identify antiretroviral therapy modification strategies to reduce cardiovascular risk
|
Interactive Case Challenges
Selection of an Initial Regimen for a Patient With a Family History of Cardiovascular Disease
|
|
|
William G. Powderly, MD, challenges your knowledge of assessing cardiovascular risk for this patient as you select his initial regimen.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List parameters that are important in assessment of cardiovascular risk in HIV-infected patients
- Describe the role of modifying traditional risk factors in management of cardiovascular risk in HIV-infected patients
- Discuss the role of antiretroviral selection as part of a strategy of lipid management for HIV-infected patients
|
Management of Dyslipidemia in an HIV-Infected Man With Grave Cardiac Risk
- Jens D. Lundgren, MD, DMSc
- Signe Westring Worm, MD
|
|
|
Jens D. Lundgren, MD, DMSc, and Signe W. Worm, MD, guide participants through the assessment of cardiac risk and treatment choices in a middle-aged patient with a high risk of a cardiovascular event.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Name the factors that are included in the assessment of 10-year cardiovascular risk by the Framingham calculation
- Discuss guideline recommendations for treatment of dyslipidemia in HIV-infected patients
- Describe the role of statins in the treatment of dyslipidemia in HIV-infected patients
- Explain how modification of antiretroviral therapy contributes to the management of dyslipidemia in HIV-infected patients
|
Slideset Module
Update on Cardiovascular Risk and Antiretroviral Therapy
- Andrew Carr, MBBS, MD, FRACP, FRCP
|
|
|
Andrew Carr, MD, reviews current data that have advanced our knowledge of cardiovascular risk in HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review current data on cardiovascular risk factors in HIV-infected patients
- Describe the recommendations for clinical management of lipids in HIV-infected patients
- Discuss the role of antiretroviral selection and modification as part of a strategy of lipid management for HIV-infected patients
|
Downloadable Slides: Update on Cardiovascular Risk and Antiretroviral Therapy
 |
|
Andrew Carr, MD, reviews current data that have advanced our knowledge of cardiovascular risk in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.54 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|